OTTAWA, Jan. 08, 2021 (GLOBE NEWSWIRE) -- The global regenerative medicine market is representing impressive CAGR of 16.1% during the forecast period 2020 to 2027.

Regenerative medicine is the division of medicine that promotes methods to repair, regrow or replace injured or diseased tissues, organs or cells. Regenerative medicine comprises of the formation and use of remedial stem cells, manufacturing of artificial organs, and tissue engineering. The combinations of tissue engineering, cell and gene therapies can strengthen the natural healing procedure in the places it is desired most, or occupy the role of a permanently injured organ. Regenerative medicine is a rather new field that connects experts in chemistry, biology, engineering, computer science, robotics, medicine, genetics and other domains to find explanations to some of the most interesting medical problems confronted by humankind.

Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1176

Growth Factors:

Factors such as increasing prevalence of chronic disorders and genetic disorders, increasing popularity of stem cells, increasing number of trauma emergencies is driving the growth of regenerative medicine market. An illness or disorder that usually persists for 3 months or longer and might get worse over a period is termed as chronic disorder. Chronic diseases mostly occur in the elderly people and can typically be controlled but not repaired. The most prevalent types of chronic ailments are heart disease, arthritis, cancer, diabetes, and stroke. Cardiovascular disorders are the biggest cause of deaths worldwide. As per the WHO data, deaths due to cardiovascular disorders represent almost 31% of the deaths globally. Almost 85% of these demises are due to stroke and heart attack. Diabetes is another most prevalent chronic ailment that affects millions of people globally. According to International Diabetes Federation (IDF), around 463 million adults (age group: 20-79 years) are battling with diabetes and by the year 2045 the number will rise to a staggering 700 million. Furthermore, approximately 75% of all health care expenses are owed to chronic ailments. Four out of the five most costly health conditions are chronic disorders such as cancer, heart disease, pulmonary conditions, and mental disorders. Regenerative medicine approaches such as stem cell therapy can cure the chronic ailments such as diabetes and arthritis, which otherwise require lifetime of medications.

The role of regenerative medicine in post trauma recovery is constantly evolving as more and more research is showing positive results. The use of regenerative medicine can be a landmark moment in the history of healthcare that will transform the treatment of chronic ailments and trauma related conditions. Thus, the high incidence of chronic ailments is driving the growth of regenerative medicine market.

View Full Report with Complete ToC@ https://www.precedenceresearch.com/regenerative-medicine-market

Regional Analysis:

The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2019, North America dominated the global market with a market share of more than 45%. U.S. represented the highest share in the North American region primarily due to constant activity in the field of drug discovery and tissue engineering. Moreover, early adoption of latest healthcare technologies also contributed to the high market share of the United States.

Europe was the second important market chiefly due to favorable reimbursement scenario and presence of latest healthcare infrastructure. The presence of skilled researchers in the European region is also expected to boost the demand for regenerative medicine market in the near future. Asia Pacific is anticipated to grow at the maximum CAGR of around18% in the forecast period due to high incidence of trauma cases and chronic disorders. Latin America and the African and Middle Eastern region will display noticeable growth.

Report Highlights:

Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1176

Key Market Players and Strategies:

The major companies operating in the worldwide regenerative medicine are Integra Life Sciences Corporation, Aspect Biosystems, Amgen, Inc., Medtronic plc, AstraZeneca, Novartis AG, Smith & Nephew plc, MiMedx Group, Shenzhen SibionoGeneTech Co., Ltd., and Baxteramong others.

High investment in the research and development along with acquisition, mergers, and collaborations are the key strategies undertaken by companies operating in the global regenerative medicine market. Recently Fuse Medical, Inc., an evolving manufacturer and supplier of innovative medical devices for the spine and orthopedic marketplace, declared the launch of FuseChoice Plus and FuseChoice Umbilical and Amniotic Membranes, and FuseChoice Plus Amniotic Joint Cushioning Fluid, the newest additions to a wide-ranging line of biologics product offerings.

Market Segmentation

By Product

By Application

By Geography

Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1176

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 774 402 6168

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

For Latest Update Follow Us:

https://www.linkedin.com/company/precedence-research/

https://www.facebook.com/precedenceresearch/

Tweets by Precedence_R

See the original post:
Regenerative Medicine Market to Reach Valuation US$ 23.7 Bn by 2027 - GlobeNewswire

Recommendation and review posted by Bethany Smith

Dublin, Jan. 06, 2021 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Cell and Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cell & gene therapy market.

Major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio and Fibrocell Science.

The global cell and gene therapy market is expected to decline from $6.68 billion in 2019 to $6.92 billion in 2020 at a compound annual growth rate (CAGR) of 3.61%. The slow growth is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $13.23 billion in 2023 at a CAGR of 24.10%.

The cell and gene therapy market consists of sales of cell and gene therapies by entities (organizations, sole traders and partnerships) that develop cell and gene therapies. Cell therapy refers to the transfer of intact, live cells that are originated from autologous or allogenic sources and gene therapy refers to the introduction, removal, or change in the genome for treating diseases. The market consists of revenue generated by the companies developing cell and gene therapy products by the sales of these products.

North America was the largest region in the cell and gene therapy market in 2019. It is also expected to be the fastest-growing region in the forecast period.

In December 2019, Roche, a Swiss multinational healthcare company, acquired Spark Therapeutics for $4.3 billion. The acquisition supports the commitment of Roche to bring transformational therapies and innovative approaches to people with serious illnesses. Spark Therapeutics will continue to work within the Roche Group as an independent company. Spark Therapeutics, headquartered in Philadelphia, is a fully integrated commercial company involved in the discovery, production, and distribution of gene therapies for genetic disorders including blindness, hemophilia, lysosomal storage, and neurodegenerative diseases.

The cell and gene therapy market covered in this report is segmented by product into cell therapy; gene therapy and by application into oncology; dermatology; musculoskeletal; others.

Limited reimbursements preventing patients from receiving treatments are expected to limit the growth of cell and gene therapy (CGT market. In 2019, Trinity Life Sciences, a life sciences solution provider, researched national and large regional commercial health insurance plans in the US. It found that the confluence of increasing price, patient volume and number of CGTs on the market is likely to change the reimbursement model for CGTs and impact payer budgets by 5-10%. Payers realize that financing needs to be generated for cost management due to the uncertainty surrounding reimbursement of ancillary costs. Limited reimbursements and uncertain insurance plans are preventing patients from receiving high-cost CGT, which is expected to limit market growth.

Chimeric antigen receptor (CAR) T-cell therapy is shaping the cell and gene therapy (CGT) market. (CAR) T-cell therapy is a combination of cell and gene therapy in which T cells are collected from the patient's blood and are genetically engineered to produce modified receptors at their surface, known as chimeric antigen receptors (CARs). These modified T cells with special structures (receptors) are reinfused into the patient. Then, the modified receptors of T cell help in targeting the surface antigen of the cancer cell that ultimately results in the killing of tumor cells in patients.

In 2020, the US-FDA approved Bristol-Myers Squibb's two CAR-T cell therapies to treat lymphoma and multiple myeloma and is set to be launched. Currently, FDA approved CAR-T cell therapy treatments like Tisagenlecleucel for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in children and Axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.

Steady investment and consolidation in cell and gene therapies contributed to the growth of the cell and gene therapy (CGT) market. After recognizing the potential of the CGT market, 16 out of the 20 largest biopharma companies by revenue, added CGT products to their portfolio.

Key Topics Covered:

1. Executive Summary

2. Cell And Gene Therapy Market Characteristics

3. Cell And Gene Therapy Market Size And Growth 3.1. Global Cell And Gene Therapy Historic Market, 2015 - 2019, $ Billion 3.1.1. Drivers Of The Market 3.1.2. Restraints On The Market 3.2. Global Cell And Gene Therapy Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion 3.2.1. Drivers Of The Market 3.2.2. Restraints On the Market

4. Cell And Gene Therapy Market Segmentation 4.1. Global Cell And Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global Cell And Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. Cell And Gene Therapy Market Regional And Country Analysis

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/yvp1rq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Link:
Global Cell and Gene Therapy Market Report 2020-2030: COVID-19 Impacts, Growth and Changes - GlobeNewswire

Recommendation and review posted by Bethany Smith

The hunt for effective therapies for solid tumors has heated up in early 2021 with a string of biotechs touting big investor checks and name-brand collaborations to chase those hard-to-treat lumps. Now, with one of its candidates already in the clinic for leukemia, Mana Therapeutics is taking a new round of funding to join the fray.

On Friday, Mana unveiled a $35 million Series A financing round that will help push the Boston-area biotechs lead candidate through a Phase I trial and could help the company secure an IND for an off-the-shelf allogeneic molecule targeting transplant-ineligible AML and solid tumors within the year.

The biotechs leading molecule, dubbed MANA-312, is already engaged in the Phase I study of patients with acute myeloid leukemia, myelodysplastic syndrome after undergoing an allogenic hematopoietic stem cell transplantation. Manas goal is to use its technology to create an inventory of off-the-shelf allogeneic products that can treat the majority of patients with certain targeted cancer indications using whats called a human leukocyte antigen matching system.

Its a different take on a similar line of attack for solid tumors: using the bodys natural immune system to educate healthy cells already in the body to target antigens on the surface of the tumors cancer cells without damaging the otherwise healthy cells. To do this, Mana uses an in-house platform called EDIFY, which it says leverages natural immune system pathways to educate T cells to target multiple cell surfaces and intracellular tumor-associated antigens.

Through multiple antigen targeting processes, the companys technology is designed to prevent the tumors immune escape, and it says the allogeneic method which uses healthy donor cells to create a master cell bank and is then used for specific therapies of attacking the solid cancer tumors could provide superior efficacy to single antigen and other cell therapy approaches.

MANA-312 also isnt the biotechs only candidate in the works. MANA-412 is a preclinical off-the-shelf allogeneic cell therapy for treating transplant-ineligible acute myeloid leukemia and solid tumors and could be ready for an IND filing by the end of the year, Mana said. The Series A round will help fund preclinical development for that candidate as well.

Mana was founded based on research and human proof-of-concept clinical trials conducted by Catherine Bollard of Childrens National Hospital and her colleagues at Johns Hopkins Medical Center. Those trials, in both solid and hematologic tumors, supported a strong safety profile, showed immunological anti-tumor activity and validated MANAs initial set of tumor antigens, the company said. Then Bollard co-founded the company with industry vet Marc Cohen. Ex-Gilead exec Martin Silverstein is the CEO.

The human proof-of-concept trials conducted by my team and colleagues showed potential for a nonengineered approach to educating T-cells to attack multiple tumor antigens, which MANA is expanding even further through refinement of the manufacturing process for an allogeneic product and application to a broader set of antigens in a variety of clinical indications and settings, Bollard said in a statement.

MANAs $35 million financing round was led by Cobro Ventures and Lightchain Capital and joined by LifeSci Venture Partners with other undisclosed investors.

See the original post:
Mana joins the hectic fight against solid tumors with an 'off-the-shelf' candidate angling for an IND this year - Endpoints News

Recommendation and review posted by Bethany Smith

Dive Brief:

As the name suggests, biomolecular condensates are tiny concentrations of molecules found inside cells. Scientists have observed these clusters, which take the form of liquid-like droplets, for decades, but only recently determined that they help regulate cellular reactions and activities.

Like other cell-managing structures, researchers suspect that biomolecular condensates can give rise to a variety of diseases if they malfunction. This thinking has led to the formation of several new drug companies in the last couple years, with Dewpoint being the first to come out of stealth mode.

Dewpoint arrived in early 2019, backed by the venture capital firm Polaris Partners and a string of other investors. Company leadership said the initial focus would be cancer and neurodegenerative diseases, though other areas like immunology and infectious disease also appear to be on Dewpoint's radar. The Boston-based biotech quickly drew interest from pharmaceutical giants, too, with Bayer and Merck & Co. inking separate deals potentially worth $100 million or more.

With the Pfizer deal, Dewpoint joins a handful of companies targeting DM1. Audentes Therapeutics, a gene therapy developer now owned by Astellas, has been exploring two approaches to treat the disease. Vertex and CRISPR Therapeutics also recently expanded a gene editing partnership to include DM1 and Duchenne muscular dystrophy.

Faze Medicines has its sights set on DM1 as well. The Cambridge, Massachusetts-based biotech debuted in December with $81 million in Series A funding, which was supplied, in part, by some big pharmaceutical firms, including the Novartis Venture Fund and AbbVie Ventures.

Faze is also trying to find and develop treatments for ALS. Interim CEO Cary Pfeffer recently told BioPharma Dive that Faze may take aim at other neurological and neurodegenerative disorders, as well as cancer, immune diseases and viral illnesses.

See the original post:
Dewpoint forges another big pharma partnership and a potential rivalry - BioPharma Dive

Recommendation and review posted by Bethany Smith

A little less than two years after bagging an extended $50 million Series C, IsoPlexis and its proteomic barcodes for personalized cancer care are back setting hooks to bring even more investors on board. And this time, theyve caught a big fish.

Perceptive Advisors is leading a $135 million Series D round for the company, the firms announced Thursday, comprising $85 million in equity and a $50 million line of credit. IsoPlexis plans to use the proceeds to expand commercial and R&D staff, increase operational capacity and accelerate product development.

The Branford, CT-based company works with cancer centers and biopharma companies in the US, Europe and China, using its biomarker-driven system designed to predict responses to such treatments and personalize treatment for patients. IsoPlexis employs a proprietary single-cell analysis tool to refine its immunotherapies.

We believe the future of advanced medicines will rely upon deeper access to in vivo biology for the development of new therapies and are excited to back the team at IsoPlexis, Perceptive portfolio manager Sam Chawla said in a statement.

Researchers have developed what they call proteomic barcode chips, which allow them to look at the entire complement of proteins within a patients cells. Its a process they say provides the mapping of new and accessible layers of biological data for every single cell, ultimately allowing for a better understanding of how individuals may respond to therapies.

Essentially, patients receive samples of these chips, which CEO Sean Mackay says is barcoded with antibodies. After the company receives the sample back, they place it into their system to see just how a persons immune system would respond to different treatments.

We call that the single-cell immune landscaping, Mackay told Endpoints News. What were able to do with that is find subsets of powerful immune cells that you typically miss in bulk profiling, sort of status quo, and that is a product that works on our instrument, basically a software-enabled system that reads out what the chips look like and what the proteins are per cell.

That software then lets IsoPlexis compare whats typically missed in that bulk profiling to long-term responder patients in several different fields like cancer immunotherapy, cell and gene therapy, Covid-19 and autoimmune disease, among other areas. IsoPlexis can then pick and choose the appropriate preclinical treatments and biomarkers in the clinic, packaging that info to pharma companies and academic labs.

Perceptive, historically a passive investor that enjoys clinical-stage investments and crossover rounds, has been fairly busy over the last year or so. It made its first foray into the company formation and Series A spaces in late 2019, setting up a $210 million early-stage VC fund with Xontogeny. Then last August, they launched their first in-house start-up in China, followed by a $310 million raise a few months later. Perceptives third SPAC also filed for an IPO in late July.

Other new investors included Ally Bridge Group and funds and accounts managed by BlackRock. Unnamed existing investors also participated in the round.

Here is the original post:
IsoPlexis scores big backer for personalized protein 'barcodes' as Perceptive jumps on board new funding round - Endpoints News

Recommendation and review posted by Bethany Smith

LONDON--(BUSINESS WIRE)--The soft tissue repair market is poised to grow by USD 10.44 billion during 2020-2024, progressing at a CAGR of over 11% during the forecast period.

Worried about the impact of COVID-19 on your Business? Here is an Exclusive report talking about Market scenarios, Estimates, the impact of lockdown, and Customer Behaviour.

Get FREE Sample Report in Minutes!

The report on the soft tissue repair market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by the rising incidence of accidental injuries.

The soft tissue repair market analysis includes Product segment and Geography Landscape. This study identifies the growing demand for gene therapy as one of the prime reasons driving the soft tissue repair market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The soft tissue repair market covers the following areas:

Soft Tissue Repair Market SizingSoft Tissue Repair Market ForecastSoft Tissue Repair Market Analysis

Companies Mentioned

Related Reports on Health Care Include:

Cosmetic Surgery Market by Type and Geography - Forecast and Analysis 2020-2024: The cosmetic surgery market size has the potential to grow by USD 11.24 billion during 2020-2024, and the markets growth momentum will accelerate during the forecast period. To get extensive research insights: Click and Get FREE Sample Report in Minutes!

Medical Textiles Market by Application, Product, and Geography - Forecast and Analysis 2020-2024: The medical textiles market size will grow by USD 2.99 billion during 2020-2024. The markets growth momentum will accelerate during the forecast period because of the market drivers, which have been explored in this report. To get extensive research insights: Click and Get FREE Sample Report in Minutes!

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Product

Market Segmentation by Application

Market Segmentation by End-user

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read more from the original source:
Global Soft Tissue Repair Market- Featuring 3M Co., Arthrex Inc., and Baxter International Inc. Among Others - Business Wire

Recommendation and review posted by Bethany Smith

In an effort to crack the code of hard-to-treat solid tumors, biopharma has tried numerous pathways to effectively target those masses without damaging healthy tissues. Phillys Carisma Therapeutics thinks it has a winner with its macrophage cell-based CAR-M candidates, and now its taking a new flush of investor cash to try one in the clinic.

Carisma has scored a $47 million Series B round to take its lead candidate, anti-HER2 CAR-M tumor fighter CT-0508, into a Phase I trial as well as advancing the rest of its preclinical macrophage pipeline. Carisma has keyed in on the use of targeted macrophage cells and vectors to penetrate the environment of solid cancer tumors without hurting health tissues a puzzle in the solid tumor field.

CT-0508s early-stage study will turn out the first human data for a CAR-M therapy based on those macrophage cells, Carisma said. CEO Steven Kelly told Endpoints News his company could offer an effective and safer way to target tumors and warm them up for the immune system to attack.

There are a number of characteristics about macrophages that would lend themselves towards applications of solid tumors and other indications, but what were focused on is solid tumors, Kelly said. Macrophages are preferentially recruited into a tumor microenvironment, and lymphocytes like the CAR-T approaches are actively excluded. So we think that we have an advantage by overcoming trafficking limitations to solid tumors.

This has been the sticking point for the industry: therapeutics that can invade the walls which surround cancerous tumors without damaging otherwise healthy cells.

Kelly is confident that Carismas technology will ultimately decipher how to do just that.

Once it starts eating (the cancerous tumor cells), the macrophages will start producing cytokines that effectively warm up that environment and convert an immunologically cold tumor into a warm or hot tumor and recruit in other cells, like T cells for example. So that last element is really unique to macrophages due to the antigen presentation capability, he said. They engage in cells directly, they warm up the tumor microenvironment, and they generate a true adaptive immune response. Thats how we think of ourselves and how were differentiated in the cell therapy space.

Kelly said it was a bit premature to know when Carisma would begin public readouts of the data surrounding its macrophage therapeutics, but he hoped they would be able to do so by the middle of this year.

The total capital Carisma has raised since its Series A financing in 2018 now totals roughly $109 million, and is a key step in moving the company from effectively a discovery-stage company to a clinical-stage company, Kelly said.

A lot of effort has gone into building this company. We had to transition from a bench project at (the University of) Penn, we had to demonstrate all the things necessary to get an IND declared (so) safety and efficacy we had to develop a GMP manufacturing process, Kelly said. All those were effectively developed to FDA satisfaction, and were moving into the clinic now.

Investors in the Series B financing are led by Symbiosis II, with subsequent investment from Solasta Ventures and Livzon Pharmaceutical Group. Additionally, Carisma said, existing investors AbbVie Ventures, HealthCap, Wellington Partners, IP Group, TPG Biotech, Agent Capital, and MRL Ventures Fund contributed to the new round of funding.

Read more from the original source:
Looking to solve the solid tumor puzzle box, Carisma aims to take 'CAR-M' groundbreaker into early-stage trial - Endpoints News

Recommendation and review posted by Bethany Smith

Investors like to see big plans, and Kevin Judice has plenty. The DiCE Molecules CEO is plotting a clinical trial launch for the biotechs lead small molecule for psoriasis and wants to double the staff in the next year and a half.

On Friday, those big plans landed him an $80 million Series C round.

Were very excited about it, he said of the raise led by RA Capital Management.

The round comes around two years after a $50 million Series B. While the B round was used for optimizing technology and building a pipeline, Judice says the Series C will propel the biotechs IL-17 antagonist to the clinic and fund the development of two other undisclosed programs.

This new capital allows us to expand our reach and get at more targets and have more opportunities to make high impact, Judice said.

DiCEs development process revolves around its DNA-encoded library. Such libraries allow researchers to screen millions even billions of compounds in parallel, using DNA tags that Judice compared to barcodes, which tell you what the constituent pieces of a molecule are.

Usually you do some kind of screen, like a high-throughput screen, or a DNA-encoded library screen, something like that, and you get a few hits. And then theres a long phase of just lab chemistry, where youre making individual compounds and trying to progress those hits, those initial binders, to something thats closer to a drug, Judice said.

That hit-to-lead phase is typically labor-intensive and slow, the CEO said. But DiCEs approach accelerates that work by using a smaller DNA-encoded library much smaller but richer in information, Judice said to screen in different ways after getting a hit.

What were actually looking for is the difference between just binding and something that is functional, Judice said.

DiCEs lead program is an agonist for cytokine receptor IL-17, which is implicated in diseases like psoriasis and psoriatic arthritis. Current antibody treatments targeting IL-17 are quite effective at treating psoriasis, but they are injectable and lack in convenience. DiCEs candidate would be oral, and the biotech is hoping to top the efficacy of Amgens already approved oral PDE4 inhibitor Otezla.

What were working on is an oral that will work as well as the anti-IL-17 antibodies. So it combines the convenience and safety of something like Otezla with the efficacy of an antibody like Cosentyx, Judice said. The antibodies tell us that IL-17 is exactly the right target.

Since 2017, DiCE has grown from a seven-person, peanut-sized company to a 29-person staff. And in the next 18 months, Judice is looking to bring that number to 58. The biotech inked a $2.3 billion discovery pact with Sanofi years ago, and is currently partnering with them on an I-O small-molecule program that Judice says isnt far behind the IL-17 candidate.

We should be ready to go public with more data on earlier programs over the course of the next 12 months. And then Im really excited about the opportunity to grow the pipeline by adding new programs to it, he said. Thats one of the things that is particularly great, from my perspective, about having RA Capital lead this round.

In addition to RA, Eventide Asset Management, New Leaf Venture Partners, Soleus Capital, Driehaus Capital Management, Osage University Partners and Asymmetry Capital Management, Northpond Ventures, Sands Capital, Sanofi Ventures, Alexandria Venture Investments, Altitude Ventures and Agent Capital also chipped into the Series C.

Here is the original post:
DiCE gets its 'library' card ready as it speeds development of DNA database-derived molecules with more investor cash - Endpoints News

Recommendation and review posted by Bethany Smith

By my calculations, Ive gone for treatment a total of 112 times in the past 6 years. Ive had approximately 23 scans, give or take a few due to brain scans, Ive had my heart checked at least 20 times, and blood draws somewhere around 30 times. Add to that oncologist appointments, primary care appointments, mental health appointments, a brief (but impactful) stint in physical therapy, as well as appointments Ive forgotten, and it becomes very clear to me why I struggle with the idea of celebrating a cancerversary that falls during the period of making New Years resolutions.

Like birthdays, Im counting up but there is a lot of the bittersweet when it comes to cancer milestones. I am thrilled to have lived a remarkable six years with metastatic breast cancer, but theres not a lot Ive forgotten about the first year following my diagnosis. It was a steep learning curve featuring fear, loss and gradual understanding along the way.

And yet, with six years in the rearview mirror, the road in front is still mostly the same for all of us. The number of people dying each year from metastatic breast cancer in the United States remains tragically high at over 40,000. The length of those lives at diagnosis remains mostly short. Just 27% of women with metastatic breast cancer and 22% of men are alive at five years from the date of their diagnosis. Theres been progresstoo often in the form of drugs that are so rough on our bodies that some choose to forgo them for the short life extension they promisebut theres been so much pain as well. Its hard to celebrate being here when friends have died far too soon or are facing the end of their treatment options.

Yet, the hope of the cancerversary is real this year.

I look back at my six years of metastatic breast cancer and thereve been two high school graduations with a third on the horizon, a college graduation, good times with good friends and trips to see the people I love. Ive packed a lot into six years and felt it all, good and bad. Year seven, starting at the same time as enormous changes in our country including a new President, new vaccines for COVID-19, renewed hope, seems like the right time to take note of a full six years of life when what I expected at the start was so much less.

So, while Im not fully celebrating, I am aware of all that I would have missed. I am spending this month in thanks for the people whove kept me here, from my friends to my oncologist to the researchers whove put their careers directly in my unplanned path. I am acknowledging the fear I felt that lingers and the love that encircles me even when we cant give one another hugs. Life is short and it is often far shorter with cancer.

Year 7 may be too much like Year 6, where months of doing so very little other than what was devoted to cancer sometimes made it feel endlessly empty, but somehow the future seems to be stretching out in front of me in this moment. Acknowledging a cancerversary in the midst of this particular new year seem like the proper expression of hope. Heres to my Year 7 and to 2021may it be good to us all.

Originally posted here:
Looking At Year Seven On This Cancerversary - Curetoday.com

Recommendation and review posted by Bethany Smith

Sustaining production from mature brownfields is becoming an uphill task in the current storm of pandemic plus economic crisis. In this years papers on mature fields and well revitalization, I have found operators focusing on making all-out efforts to improve their ongoing waterflood operations to extend the life of existing wells, which is preferred over drilling new infill wells.

Waterflooding is the oldest method used for secondary recovery in oil fields because water is readily available and relatively inexpensive. Although the concept behind waterflooding is relatively simple and easy to implement, the reality is different, with many potential challenges such as water circulation because of poor reservoir conformance, induced matrix fracturing resulting in early water breakthrough, and reservoir souring, to mention just a few. The older the waterflood, the more susceptible it becomes to problems and challenges, and the most unavoidable challenge is managing increased amounts of produced water.

A third of the papers studied this year focus on improved-/enhanced-oil-recovery techniques, and a majority of them focus on improving waterfloods through various techniques such as using classical analysis and data-driven technologies for redistributing injected water and integrating efforts with cross-disciplinary teams.

Another area of focus is extending the life of existing wells. It is both a challenge and an opportunity. It is a challenge because operators must find a delicate balance between extending the life of an old well and jeopardizing the safety and integrity conditions in the field. It is an opportunity because it provides an attractive alternative for identifying and appraising possible behind-casing opportunities before plugging and abandonment. Several studies have been conducted to identify and appraise such opportunities.

Natural Dumpflood in Malaysia Succeeds as Low-Cost Offshore Oil-Recovery Method

Fracturing With Height Control Extends the Life of Mature Reservoirs in the Pannonian Basin

Analytical Work Flows Enable Continuous Waterflooding Optimization for a Mature Field

IPTC 19763 Chasing Behind-Casing Opportunities in Low-Salinity Laminated Brown Reservoirs by Noor Faezah Ramly, Petronas, et al.

SPE 199205 Standardization of Inactive Wells-Audit Process for Well Abandonment and Production Enhancement Candidate Screening by Elin Haryanto, Schlumberger, et al.

SPE 197474 Prevention of Well-Control Incidents and Well Life Extension in Mature Fields by Andrey Yugay, ADNOC, et al.

Read the original post:
JPT Mature Fields and Well Revitalization - Journal of Petroleum Technology

Recommendation and review posted by Bethany Smith

WASHINGTON The first full year for the U.S. Space force marked an eventful stretch for the military in space.

From the growth of the nascent military branch to the award of massive new launch contracts, 2020 was a busy year in the space domain. Just this December, the Trump administration formalized its thinking about space in a new National Space Policy and gave Space Force members a surprise birthday gift: an official name. With new developments, launches and announcements spilling out throughout this year, even the most ardent observers could be forgiven for missing a story or two.

And so without any more bloviating heres a recap of the top six military space stories of 2020.

The Space Force takes shape

While history will note 2019 as the year the Space Force was created, 2020 was the year the new service began to take shape.

Chief of Space Operations Gen. John Jay Raymond says his team had five focus areas for year one of setting up the first new branch of the military in 70 years: developing its people, developing its doctrine, presenting an independent budget, designing the force and presenting forces to a joint command. Raymonds team has arguably made strides in all of those areas.

In 2020, the Space Force got its first member and chief of space operations, added 2,500 people to the new service, defined spacepower as distinct from military power in its capstone doctrine, set up the first of three commands, began implementing a series of acquisition reforms, and gave its personnel their official name: guardians. Questions remain, such as which capabilities and offices will transfer to the Space Force from the other services and what the new Space Systems Command will look like. Still, Raymond was optimistic about the progress made in year one.

As I look back on this first year, I look back with great pride great pride for the work that our space professionals have done in establishing this new service, said Raymond in a December media call. The progress we have made far surpasses anything I would have expected. We have completely reorganized the national security space organization the largest restructure in our history.

Sign up for the C4ISRNET newsletter about future battlefield technologies.

(please select a country) United States United Kingdom Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of The Cook Islands Costa Rica Cote D'ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Democratic People's Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia and Montenegro Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe

Subscribe

By giving us your email, you are opting in to the C4ISRNET Daily Brief.

Space Development Agency orders first satellites

When the Trump administration created the Space Development Agency in March 2019, the office was a bit of an enigma. While most observers called for the consolidation of space systems acquisitions, the Trump administration established a new agency outside the purview of the U.S. Air Force. Furthermore, experts questioned whether the agency would survive the year, especially with the establishment of a Space Force imminent.

But in 2020, SDA defined its place in the nations space enterprise: building a new National Defense Space Architecture that will be made up of hundreds of satellites in low Earth orbit. The core of that architecture a space-based mesh network will serve as the space component of Combined Joint All-Domain Command and Control, the Pentagons effort to connect any sensor to any shooter across services and domains.

And while the agencys biggest advocate in the Pentagon Under Secretary of Defense for Research and Engineering Mike Griffin left the government for the private sector, the office moved forward confidently in soliciting and awarding its first contracts over the summer. In August, the agency awarded York Space Systems $94 million and Lockheed Martin $188 million to build 10 satellites each for the inaugural transport layer. Then in October, the agency issued contracts for its first eight missile tracking satellites: $149 million for SpaceX and $193 million for L3Harris. A protest from Raytheon Technologies is holding up the tracking layer satellites, though SDA says it is taking corrective action and working to keep the effort on track for a 2022 delivery.

SpaceX and ULA win massive launch contracts

In one sense, the story of 2020 could be the emergence and success of several small launch providers despite a global pandemic. Yet the biggest launch contract of the year was for traditional heavy launches. In August, the Space Force issued its National Security Space Launch contract to SpaceX and United Launch Alliance, with the former receiving $316 million and the latter receiving $337 million.

The National Security Space Launch contracts will support more than 30 heavy lift launches for the Space Force and National Reconnaissance Office over a five-year period from fiscal 2022 through 2027. Under the arrangement, 60 percent of launch services orders will go to ULA, with SpaceX taking up the remainder.

While the award is a major victory for SpaceX, which has fought tooth and nail to force its way into the lucrative military heavy lift launch market, it is undoubtedly frustrating for the two companies left out Northrop Grumman and Blue Origin which had been developing new rockets as part of the competition.

On-orbit servicing presents new opportunities

2020 marked the first successful docking of two commercial satellites on orbit as part of a commercial satellite life extension service offered by Northrop Grummans SpaceLogistics. That service involves attaching a SpaceLogistics Mission Extension Vehicle to an Intelsat communications satellite with depleted fuel reserves. By supplementing the satellites fuel reserves with its own and effectively towing the client around orbit, the MEV is expected to stretch the satellites service life by five years.

While the mission was entirely commercial, it has major implications for the military, which is looking into using SpaceLogistics services to extend the lives of its own satellites.

And commercial on-orbit satellite servicing could extend far beyond simply supplementing empty fuel reserves. Following the successful docking in February, SpaceLogistics announced a partnership with the Defense Advanced Research Projects Agency on the Robotic Servicing of Geosynchronous Satellites (RSGS) program, which is working to create the first commercial spacecraft with a robotic arm that can perform repairs, augmentation, assembly, inspection or relocation of other spacecraft already on orbit.

SpaceLogistics is understandably bullish about the prospect of the military purchasing life extension services, and the Department of Defense has expressed interest. Other companies are eager to compete to provide those services. Most notably, Astroscale entered the field in June, providing its own slate of on-orbit servicing solutions.

Perhaps on-orbit servicing wont be as feasible or cost effective as hoped, but 2020 was the year the concept became a reality.

Russia continues anti-satellite weapons testing

Throughout 2019 and 2020, the Pentagon used the development and testing of anti-satellite weapons by Russia and China as a justification for establishing the Space Force. And in 2020, Russia provided plenty of fodder for those who believe that nations space activities are provocative, to say the least.

In 2020, the Russian government conducted two tests of a direct-ascent anti-satellite missile, capable of taking out satellites in low Earth orbit. While Russia has tested such missiles in the past, pushback from the newly established U.S. Space Command brought the issue to the fore in 2020. The 11th combatant command was quick and direct in calling out the tests, which it characterized as aggressive.

Russias DA-ASAT test provides yet another example that the threats to U.S. and allied space systems are real, serious and growing, said Raymond, then-head of U.S. Space Command, after the first test in April. The United States is ready and committed to deterring aggression and defending the nation, our allies and U.S. interests from hostile acts in space.

The command continued its criticisms of Russia in December, when that government conducted another test.

Russia has made space a war-fighting domain by testing space-based and ground-based weapons intended to target and destroy satellites. This fact is inconsistent with Moscows public claims that Russia seeks to prevent conflict in space, Space Command head Gen. James Dickinson said. Space is critical to all nations. It is a shared interest to create the conditions for a safe, stable and operationally sustainable space environment.

But perhaps more concerning than the direct-ascent missiles was what USSPACECOM characterized as the testing of an on-orbit anti-satellite weapon. In July, USSPACECOM announced that a Russian satellite appeared to have launched a high-speed projectile into space, an action inconsistent with its stated purpose. A similar test was carried out in 2017.

U.S. officials have not shied away from characterizing this capability as a weapon especially since Russian government satellites have a habit of sidling up to U.S. commercial and government satellites.

China and Russia are continuing to develop space weaponry, said Vice President Mike Pence in December remarks to the National Space Council. Russia demonstrated a space-based anti-satellite weapon earlier this year. China is developing a new manned space station, and its robotic spacecraft will return samples from the moon in just a matter of weeks.

Army tests space-enabled sensor-to-shooter pipeline

Superficially, the Army doesnt scream space. Yet in 2020, the Army made big advances during Project Convergence that show how it plans to use new space-based capabilities to enable beyond-line-of-sight targeting.

Project Convergence is the Armys new campaign of learning, an effort to transform the battlefield with artificial intelligence, developmental networks and new sensing capabilities. In short, the Army wants to be able to connect any sensor to the best shooter. Satellites were used both as sensors to detect threats and as a network to connect sensors and shooters across the battlefield.

Tactical imagery satellites were a major part of Project Convergence. Taking images of the battlefield from their high vantage point, a satellite would downlink its data to a TITAN surrogate, where artificial intelligence was then used to process that imagery, automatically detect threats, and provide targeting data to Army shooters. In this new setup, satellites can provide the essential sensing capability to enable beyond-line-of-sight targeting.

The Army also tapped into new commercial satellite networks in low Earth orbit to connect its systems. Using proliferated constellations such as SpaceXs Starlink, the Army was able to transport data hundreds of miles in just seconds. Army officials say they will be able to experiment with even more capacity at Project Convergence 2021, as the commercial constellations become more mature.

All told, those space-based capabilities helped cut down the sensor-to-shooter timeline from 20 minutes to 20 seconds.

I can tell you with confidence, there isnt a person in the Army now who doesnt understand or isnt able to appreciate the capability that this deep sensing capability from space provides now, Willie Nelson, director of Army Futures Commands Assured Positioning, Navigation and Timing Cross-Functional Team, told C4ISRNET following the exercise. Theres not a dry eye in the room when you look at how fast we can rapidly find threats and get those to shooters.

Much, much more to come

Missing your favorite military space development of 2020? Perhaps you were more interested in the relaunch of the secretive X-37B space plane, the operational acceptance of M-Code Early Use, or even the completion of the Advanced Extremely High Frequency communications constellation. 2020 was a busy year to be sure, and 2021 looks to be equally enthralling as we learn about the Biden teams plans for the space domain, see how the Space Force organizes its acquisitions, and find out how the military will utilize emerging commercial space capabilities.

Follow this link:
The 6 big military space stories of 2020 - C4ISRNet

Recommendation and review posted by Bethany Smith

LOS ANGELES, United States: QY Research has recently published a research report titled, Global Magnolia Bark Extract Sales Market Report 2020. This report has been prepared by experienced and knowledgeable market analysts and researchers. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Magnolia Bark Extract market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the global Magnolia Bark Extract market.

The report includes CAGR, market shares, sales, gross margin, value, volume, and other vital market figures that give an exact picture of the growth of the global Magnolia Bark Extract market.

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Magnolia Bark Extract market.

Key questions answered in the report:

TOC

1 Magnolia Bark Extract Market Overview1.1 Magnolia Bark Extract Product Scope1.2 Magnolia Bark Extract Segment by Type1.2.1 Global Magnolia Bark Extract Sales by Type (2020-2026)1.2.2 Solid Form1.2.3 Powder Form1.3 Magnolia Bark Extract Segment by Application1.3.1 Global Magnolia Bark Extract Sales Comparison by Application (2020-2026)1.3.2 Pharmaceutical1.3.3 Food and Beverages1.3.4 Others1.4 Magnolia Bark Extract Market Estimates and Forecasts (2015-2026)1.4.1 Global Magnolia Bark Extract Sales Growth Rate (2015-2026)1.4.2 Global Magnolia Bark Extract Revenue and Growth Rate (2015-2026)1.4.3 Global Magnolia Bark Extract Price Trends (2015-2026) 2 Magnolia Bark Extract Estimate and Forecast by Region2.1 Global Magnolia Bark Extract Market Size by Region: 2015 VS 2020 VS 20262.2 Global Magnolia Bark Extract Retrospective Market Scenario by Region (2015-2020)2.2.1 Global Magnolia Bark Extract Sales Market Share by Region (2015-2020)2.2.2 Global Magnolia Bark Extract Revenue Market Share by Region (2015-2020)2.3 Global Magnolia Bark Extract Market Estimates and Forecasts by Region (2021-2026)2.3.1 Global Magnolia Bark Extract Sales Estimates and Forecasts by Region (2021-2026)2.3.2 Global Magnolia Bark Extract Revenue Forecast by Region (2021-2026)2.4 Geographic Market Analysis: Market Facts & Figures2.4.1 United States Magnolia Bark Extract Estimates and Projections (2015-2026)2.4.2 Europe Magnolia Bark Extract Estimates and Projections (2015-2026)2.4.3 China Magnolia Bark Extract Estimates and Projections (2015-2026)2.4.4 Japan Magnolia Bark Extract Estimates and Projections (2015-2026)2.4.5 Southeast Asia Magnolia Bark Extract Estimates and Projections (2015-2026)2.4.6 India Magnolia Bark Extract Estimates and Projections (2015-2026) 3 Global Magnolia Bark Extract Competition Landscape by Players3.1 Global Top Magnolia Bark Extract Players by Sales (2015-2020)3.2 Global Top Magnolia Bark Extract Players by Revenue (2015-2020)3.3 Global Magnolia Bark Extract Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Magnolia Bark Extract as of 2019)3.4 Global Magnolia Bark Extract Average Price by Company (2015-2020)3.5 Manufacturers Magnolia Bark Extract Manufacturing Sites, Area Served, Product Type3.6 Manufacturers Mergers & Acquisitions, Expansion Plans3.7 Primary Interviews with Key Magnolia Bark Extract Players (Opinion Leaders) 4 Global Magnolia Bark Extract Market Size by Type4.1 Global Magnolia Bark Extract Historic Market Review by Type (2015-2020)4.1.1 Global Magnolia Bark Extract Sales Market Share by Type (2015-2020)4.1.2 Global Magnolia Bark Extract Revenue Market Share by Type (2015-2020)4.1.3 Global Magnolia Bark Extract Price by Type (2015-2020)4.2 Global Magnolia Bark Extract Market Estimates and Forecasts by Type (2021-2026)4.2.1 Global Magnolia Bark Extract Sales Forecast by Type (2021-2026)4.2.2 Global Magnolia Bark Extract Revenue Forecast by Type (2021-2026)4.2.3 Global Magnolia Bark Extract Price Forecast by Type (2021-2026) 5 Global Magnolia Bark Extract Market Size by Application5.1 Global Magnolia Bark Extract Historic Market Review by Application (2015-2020)5.1.1 Global Magnolia Bark Extract Sales Market Share by Application (2015-2020)5.1.2 Global Magnolia Bark Extract Revenue Market Share by Application (2015-2020)5.1.3 Global Magnolia Bark Extract Price by Application (2015-2020)5.2 Global Magnolia Bark Extract Market Estimates and Forecasts by Application (2021-2026)5.2.1 Global Magnolia Bark Extract Sales Forecast by Application (2021-2026)5.2.2 Global Magnolia Bark Extract Revenue Forecast by Application (2021-2026)5.2.3 Global Magnolia Bark Extract Price Forecast by Application (2021-2026) 6 United States Magnolia Bark Extract Market Facts & Figures6.1 United States Magnolia Bark Extract Sales Market Share by Company (2015-2020)6.2 United States Magnolia Bark Extract Sales Market Share by Type (2015-2020)6.3 United States Magnolia Bark Extract Sales Market Share by Application (2015-2020) 7 Europe Magnolia Bark Extract Market Facts & Figures7.1 Europe Magnolia Bark Extract Sales Market Share by Company (2015-2020)7.2 Europe Magnolia Bark Extract Sales Market Share by Type (2015-2020)7.3 Europe Magnolia Bark Extract Sales Market Share by Application (2015-2020) 8 China Magnolia Bark Extract Market Facts & Figures8.1 China Magnolia Bark Extract Sales Market Share by Company (2015-2020)8.2 China Magnolia Bark Extract Sales Market Share by Type (2015-2020)8.3 China Magnolia Bark Extract Sales Market Share by Application (2015-2020) 9 Japan Magnolia Bark Extract Market Facts & Figures9.1 Japan Magnolia Bark Extract Sales Market Share by Company (3015-3030)9.2 Japan Magnolia Bark Extract Sales Market Share by Type (2015-2020)9.3 Japan Magnolia Bark Extract Sales Market Share by Application (2015-2020) 10 Southeast Asia Magnolia Bark Extract Market Facts & Figures10.1 Southeast Asia Magnolia Bark Extract Sales Market Share by Company (2015-2020)10.2 Southeast Asia Magnolia Bark Extract Sales Market Share by Type (2015-2020)10.3 Southeast Asia Magnolia Bark Extract Sales Market Share by Application (2015-2020) 11 India Magnolia Bark Extract Market Facts & Figures11.1 India Magnolia Bark Extract Sales Market Share by Company (2015-2020)11.2 India Magnolia Bark Extract Sales Market Share by Type (2015-2020)11.3 India Magnolia Bark Extract Sales Market Share by Application (2015-2020) 12 Company Profiles and Key Figures in Magnolia Bark Extract Business12.1 Swanson12.1.1 Swanson Corporation Information12.1.2 Swanson Business Overview12.1.3 Swanson Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)12.1.4 Swanson Magnolia Bark Extract Products Offered12.1.5 Swanson Recent Development12.2 Samsara herbs12.2.1 Samsara herbs Corporation Information12.2.2 Samsara herbs Business Overview12.2.3 Samsara herbs Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)12.2.4 Samsara herbs Magnolia Bark Extract Products Offered12.2.5 Samsara herbs Recent Development12.3 Genesis Today12.3.1 Genesis Today Corporation Information12.3.2 Genesis Today Business Overview12.3.3 Genesis Today Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)12.3.4 Genesis Today Magnolia Bark Extract Products Offered12.3.5 Genesis Today Recent Development12.4 Planetary Herbals12.4.1 Planetary Herbals Corporation Information12.4.2 Planetary Herbals Business Overview12.4.3 Planetary Herbals Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)12.4.4 Planetary Herbals Magnolia Bark Extract Products Offered12.4.5 Planetary Herbals Recent Development12.5 Solaray12.5.1 Solaray Corporation Information12.5.2 Solaray Business Overview12.5.3 Solaray Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)12.5.4 Solaray Magnolia Bark Extract Products Offered12.5.5 Solaray Recent Development12.6 Active Herb12.6.1 Active Herb Corporation Information12.6.2 Active Herb Business Overview12.6.3 Active Herb Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)12.6.4 Active Herb Magnolia Bark Extract Products Offered12.6.5 Active Herb Recent Development12.7 LiftMode12.7.1 LiftMode Corporation Information12.7.2 LiftMode Business Overview12.7.3 LiftMode Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)12.7.4 LiftMode Magnolia Bark Extract Products Offered12.7.5 LiftMode Recent Development12.8 Life Extension12.8.1 Life Extension Corporation Information12.8.2 Life Extension Business Overview12.8.3 Life Extension Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)12.8.4 Life Extension Magnolia Bark Extract Products Offered12.8.5 Life Extension Recent Development12.9 thepurehealth12.9.1 thepurehealth Corporation Information12.9.2 thepurehealth Business Overview12.9.3 thepurehealth Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)12.9.4 thepurehealth Magnolia Bark Extract Products Offered12.9.5 thepurehealth Recent Development12.10 Hawaii Pharm LLC12.10.1 Hawaii Pharm LLC Corporation Information12.10.2 Hawaii Pharm LLC Business Overview12.10.3 Hawaii Pharm LLC Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)12.10.4 Hawaii Pharm LLC Magnolia Bark Extract Products Offered12.10.5 Hawaii Pharm LLC Recent Development12.11 Piping Rock Health Products12.11.1 Piping Rock Health Products Corporation Information12.11.2 Piping Rock Health Products Business Overview12.11.3 Piping Rock Health Products Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)12.11.4 Piping Rock Health Products Magnolia Bark Extract Products Offered12.11.5 Piping Rock Health Products Recent Development12.12 Now Foods Source Naturals12.12.1 Now Foods Source Naturals Corporation Information12.12.2 Now Foods Source Naturals Business Overview12.12.3 Now Foods Source Naturals Magnolia Bark Extract Sales, Revenue and Gross Margin (2015-2020)12.12.4 Now Foods Source Naturals Magnolia Bark Extract Products Offered12.12.5 Now Foods Source Naturals Recent Development 13 Magnolia Bark Extract Manufacturing Cost Analysis13.1 Magnolia Bark Extract Key Raw Materials Analysis13.1.1 Key Raw Materials13.1.2 Key Raw Materials Price Trend13.1.3 Key Suppliers of Raw Materials13.2 Proportion of Manufacturing Cost Structure13.3 Manufacturing Process Analysis of Magnolia Bark Extract13.4 Magnolia Bark Extract Industrial Chain Analysis 14 Marketing Channel, Distributors and Customers14.1 Marketing Channel14.2 Magnolia Bark Extract Distributors List14.3 Magnolia Bark Extract Customers 15 Market Dynamics15.1 Magnolia Bark Extract Market Trends15.2 Magnolia Bark Extract Opportunities and Drivers15.3 Magnolia Bark Extract Market Challenges15.4 Magnolia Bark Extract Market Restraints15.5 Porters Five Forces Analysis 16 Research Findings and Conclusion 17 Appendix17.1 Research Methodology17.1.1 Methodology/Research Approach17.1.2 Data Source17.2 Author List17.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

https://lionlowdown.com/

Read the original here:
Comprehensive Report on Magnolia Bark Extract Market 2021 | Trends, Growth Demand, Opportunities & Forecast To 2027 - LionLowdown

Recommendation and review posted by Bethany Smith

The R/V Roger Revelle out at sea for a 10-day commissioning and calibration cruise following its midlife refit. Photo: Scripps Institution of Oceanography

Research vessel (R/V)Roger Revelleis back at work after a midlife refit involving upgrades from top to bottom, bow to stern. The primary goal of extending the service life by 15 to 20 years was accomplished with improvements to systems crucial to the vessels operations, scientific capabilities, habitability, and environmental footprint.

The ship is owned by the Office of Naval Research and has been operated by Scripps Institution of Oceanography at the University of California San Diego since 1996. It is one of the largest ships in the U.S. Academic Research Fleet, and vitally important to U.S. oceanographic research due to its range, payload, duration, and ability to safely conduct scientific operations in remote areas around the globe.

Roger Revelleisn't just revitalized, it is better than new, said Bruce Appelgate, associate director and head of ship operations at Scripps Oceanography. The midlife refit was an opportunity to apply everything we've learned about the ship since 1996, in order to make a great research vessel even more effective.

The $60 million refit, which includes the base refit cost and investment in scientific systems and instrumentation, was supported by the Office of Naval Research (ONR), National Science Foundation (NSF), and UC San Diego.

The partnership between the National Science Foundation and the Office of Naval Research in supporting the Global class vessels is one of the most important Federal alliances the Division of Ocean Science has made in safeguarding our critical sea-going science missions, said Rose Dufour, NSF Program Director.

Upgrades to R/VRoger Revelleinclude the addition of diesel engines that reduce emissions by up to two-thirds, ballast water systems designed to protect against the spread of invasive species, and the use of heat captured from the ships engine to desalinate seawater. These upgrades are the latest reflection of an ongoing effort throughout the U.S. Academic Research Fleet to reduce the environmental impact of ships.

An innovative extendable bow thruster has been installed that can be lowered beneath the ship to deliver thrust in any direction. This provides more power and quieter operations compared to the original bow thruster. Coupled with the ships dynamic positioning system, the new thruster enables it to maintain precise positioning and improves maneuverability when coming into port.

The ships overboard handling systems also got an overhaul, with new cranes and a completely refurbished A-frame and hydrographic boom used to deploy and recover scientific instruments while at sea.

Upgraded network capabilities support the significant amount of data collected from these instruments. A new virtual desktop infrastructure (VDI) includes display consoles for all systems throughout the ship, reducing the workload for scientists and crew members alike who use these during their operations. New cyberinfrastructure and centralized computer management helps the ships technicians maintain security and reliability of onboard computing and networking.

Another major upgrade was the addition of the acoustics gondola secured below the keel. This new position results in significantly improved sonar performance, enabling operations to continue even in high sea states. Acoustic systems are used to profile the subsurface, identify animals in the water column, track subsurface vehicles, and measure ocean currents. They are also used to map the seafloor, a capability much desired by the renewed effort to map the U.S. Exclusive Economic Zone through the Federal National Ocean Mapping, Exploration, and Characterization (NOMEC) Strategy, which NSF and ONR help lead.R/VRoger Revellewill now have the most sophisticated mapping capabilities in the U.S. Academic Research Fleet.

Inside the ships laboratories, reconfigurable tables feature an innovative nesting design that allows for practical and efficient use of space for scientists with a variety of needs. Improving the living and recreation spaces for everyone on board was important during the overhaul as well, particularly for crew members who make the ship their home for months at a time. Upgrades to living spaces include new carpets, bed curtains, and flooring.

The overhaul of the vessel was conducted in Portland, Ore., by Vigor Shipyard. R/VRoger Revellereturned to its home port of San Diego in July, where Scripps Oceanography technicians worked under UC San Diegos enhanced safety protocols to complete the work.

R/VRoger Revellewas put into service in 1996. It honors former Scripps Oceanography Director Roger Revelle who is widely regarded for not only establishing the institution as an internationally prominent science center, but for solidifying the decades-long relationship between Scripps Oceanography and the U.S. Navy.

Roger Revelle was a visionary who back in 1946 envisioned the Office of Naval Research as a world leader in sponsoring oceanographic basic research, and later foresaw the need for a new University of California in La Jolla that eventually grew around Scripps, said Tom Drake, director of the Ocean Battlespace and Expeditionary Access department at the Office of Naval Research. He also suggested the likely trajectory of the Earths climate, which we are now observing.

Revelle served as an oceanographer for the U.S. Navy during World War II and was instrumental in the founding of the Office of Naval Research. Roger Revelle worked at Scripps Oceanography before and after the war and served as its director from 1950 to 1964. He was among the first to consider the implications of the accumulation of carbon dioxide in the atmosphere and absorption rates of the greenhouse gas by the ocean.

A continuous profiling system under the ship will also measure carbon dioxide in seawater, an essential component of ocean acidification research.

"The revitalization of R/VRoger Revellewill enable even more scientific discoveries at sea to further our understanding of our planet, said Margaret Leinen, vice chancellor for marine sciences at UC San Diego and director of Scripps Oceanography. We appreciate the continued leadership from Congress to build and renovate the U.S. research fleet."

The first research expedition on the all-new R/VRoger Revellegot underway in early November, in an essential research mission led by UC Santa Barbara to retrieve ocean bottom seismometers measuring seismic activity and to collect rocks from seamounts and underwater volcanoes. The ship has already crossed the equator and is putting the upgraded acoustic systems to use while recovering these instruments.

Thesecond research cruise begins on Christmas day, during which R/VRoger Revelletravels to the Southern Ocean. The ships handling systems will be put through their paces as scientists collect samples, photographs, and sensor data to learn about plankton concentrations in eddies that form in the Southern Pacific. This 60-day expedition led by Barney Balch of theBigelow Laboratory for Ocean Scienceswill also deploy biogeochemical floats for theSouthern Ocean Carbon and Climate Observations and Modeling project, a multi-institution program focused on unlocking the mysteries of the Southern Ocean and determining its influence on climate.

While the enduring connection between the Navy and Scripps is manifest in the vessels namesake, this service life extension will serve multiple agencies, academic institutions and inspire the next generation of ocean-going scientists, said Rob Sparrock, program officer with the Office of Naval Research who oversees the research vessel program.

Appelgate said the refit illustrates the continued value of seagoing research vessels even as remote and autonomous observing platforms proliferate to compliment ship-based research.

Shipboard research offers the transformative potential to understand global change and monitor the health of ocean ecosystems, while training the next generation of sea-going scientists and technicians, Appelgate said.

The home port of R/VRoger Revelleis theNimitz Marine Facilityin San Diego, where the vessel is maintained as part of the Scripps oceanographic research fleet alongside the Navy-owned and Scripps-operated R/VSally Ride,the University of California-owned R/VRobert Gordon Sproul,R/VBob and Betty Beyster,and Research Platform FLIP (FLoating Instrument Platform).

Link:
Midlife refit of Scripps' Research Vessel Roger Revelle completed - Research vessel (R/V) Roger Revelle is back at work after a midlife refit...

Recommendation and review posted by Bethany Smith

By Venkatachari JagannathanChennai, Dec 31 : The year 2020 was a challenging year for the Indian atomic sector due to the Covid-19 pandemic. However, it still performed remarkably well attaining a major milestone and also taking steps towards setting up of a medical research reactor in public-private-partnership (PPP) mode, a top sector official said.

A significant milestone achieved during the year was the achievement of first criticality of KAPP-3 (Kakrapar Atomic Power Project-3), the first of a kind indigenous 700 MW Pressurised Heavy Water Reactor (PHWR), which is the first in a series of 16 such reactors being set up in the country, Atomic Energy Commission (AEC) Chairman K.N. Vyas told IANS.

The KAPP-3 attained first criticality (controlled self-sustaining nuclear fission chain reaction) in July despite the handicap of the Covid-19 lockdown.

All efforts are being made to start commercial operation of the first 700 MW unit at Kakrapar, KAPP-3 by March 2021. Work on the KAPP-4 and RAPP 7&8 (Rajasthan Atomic Power Project) is being expedited. In KAPP-4 and RAPP-7, main plant civil construction and erection of major equipment has been completed and balance activities are in progress. In RAPP-8, various construction and erection activities are in progress, Vyas said.

According to him, the nuclear power stations operated at the highest standards of safety and generated 40,718 Million Units of electricity in 11 months of this year (January to November 2020).

Continuing with the trend of setting records in long continuous operation by Indian nuclear power reactors, NAPS-2 (Narora Atomic Power Station-2) continued to operate during the year, registering 851 days of continuous operation as on December 23, 2020, Vyas added.

The year also saw Union Finance Minister Nirmala Sitharaman announcing setting up of a research reactor for production of medical isotopes in PPP mode to offer affordable treatment for cancer and other diseases.

Soon after that the Department of Atomic Energy (DAE) set the process rolling and in November, appointed the Strategic Consultant and Transaction Advisor for setting up research reactor under PPP.

The consultant is engaged from initial feasibility study to executing the concession agreement, Vyas said.

According to him, the proposed reactor is designed to maximise irradiation capacity, and thus a large quantity of variety of radioisotopes shall be produced in the reactor.

Majority of the isotopes are for medical use. In addition, some of the isotopes would also have industrial use. As per internal assessment, it is expected that with this research reactor, it will be possible to meet the complete requirement of medical isotopes in the country, Vyas said.

In addition, there will be considerable scope to export of radioisotopes. It is planned to have processing facility complex along with the reactor. It would be worlds largest (production volume wise) radio-isotopes production and processing facility, he added.

Following the appointment of the consultant, the Bhabha Atomic Research Centre (BARC) held discussions with the consultant to finalise the business case and PPP model.

To know the expectation of the industry and probable investors, A.T. Kearney has initiated dialogues with leading players/investors of the different field, Vyas said.

As regards the reactor design, the design detailing is under progress.

With several more atomic power plants planned needing fuel, attempts are being made by Uranium Corporation of India Ltd (UCIL) to increase production.

Looking forward to 2021, Vyas said, the plan is to commence commercial operation of KAPP-3 (700 MW) while work on KAPP-4 (700 MW), RAPP-7&8 (2700 MW), Kudankulam Nuclear Power Project-3&4 (21,000 MW) and Gorakhpur Haryana Anu Vidyut Pariyojana (GHAVP-2700 MW) projects are planned to be speeded up in the year after the slowdown in 2020 due to the pandemic.

In addition, start of construction of KNPP 5&6 (2X1000 MW) at Tamil Nadus Kudankulam is also planned in the year.

The year also saw transfer of 25 different technologies through 38 Transfer of Technology (ToT) agreements. The nuclear technologies transferred were developed under various fields like agriculture, bioscience, environment, medical equipment, advanced instrumentation, engineering, water, radiation and chemical.

Vyas said BARC is engaged in research and development activities related nuclear agriculture and food preservation technologies like radiation induced mutants with superior traits, development of super absorbent hydrogel for dry regions and shelf-life extension of fruits.

One Trombay crop variety TKR Kolam (Trombay Karjat Kolam) has been released and gazette notified for commercial cultivation by Ministry of Agriculture & Farmers Welfare. Two rice varieties, Vikram-TCR and CG Trombay Jawaphool were released by State Variety Release Committee (SVRC), Chhattisgarh. Breeder seed production of Trombay crop varieties was carried for groundnut (332 quintals), rice (15 quintals) and pulses (20 quintals), Vyas said.

Pointing out that drought is the most severe stress that hinders the growth of crop plants, causing substantial yield loss to farmers, Vyas said: BARC has developed a super-absorbent polymeric hydrogel using radiation technology. The hydrogel can soak up about 400 times its own weight and act as a water reservoir in the soil, releasing the stored water upon plant/root demand.

In arid areas, the use of BARC hydrogel can increase the water holding capacity of soil, which significantly improves the plant health and productivity. The hydrogel has shown potential during testing in BARC and the same is being tested with the help of State Agriculture Universities, he added.

While BARC will continue to develop and test new mutants/breeding lines of oilseed, pulses and cereals, it will also take up development of technologies for shelf life extension of fish, spreads, vegan milk made of chick pea and preservation of agriculture produce (wheat, pointed gourd etc.), Vyas remarked.

Other notable developments are the biokit for detection of group of organophosphate (OP) and organocarbamate (OC) pesticides for qualitative detection of presence of pesticides in food commodities such as vegetables and fruits and 1,000 Litre Per Hour (LPH) reverse osmosis technology based water treatment plants were commissioned at villages of Maharashtra and West Bengal in alignment with the Jal Shakti Abhiyan and Jal Jeevan Mission of the Centre, Vyas said.

(Venkatachari Jagannathan can be contacted at v.jagannathan@ians.in)

Disclaimer: This story is auto-generated from IANS service.

Excerpt from:
2020: A year of challenge and achievement for Indian nuclear sector - The Siasat Daily

Recommendation and review posted by Bethany Smith

DUBLIN, Jan. 4, 2021 /PRNewswire/ -- The "Biopreservation Market by Type, Application, End-user, and Geography - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Biopreservation is a process that assists in the conservation of biospecimens such as DNA, saliva, and plasma. This process of biopreservation generally increases the durability, shelf life, and purity of the biosamples. The types of equipment in this process include freezers, liquid nitrogen, consumables, and also media & laboratory information management systems.

This process is also used to preserve food and extend its shelf life, specifically by using lactic acid bacteria. Growth in healthcare spending is assumed for better access to quality healthcare and advanced technology products such as biopreservation facilities, thereby widening the growth expectations. Moreover, the bio-banks, hospitals, and gene banks, which are major end-users for this market, are stimulating the key providers to establish technologically advanced biopreservation products to improve patient outcomes. The Biopreservation Market is projected to grow at a rate of 9.2% CAGR by 2026.

The biopreservation market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology, along with an irreplaceable blend of primary insights. The real-time assessment of the market is an integral part of our market sizing and forecasting methodology. Our industry experts and panel of primary participants have helped in compiling relevant aspects with realistic parametric estimations for a comprehensive study. The participation share of different categories of primary participants is given below:

In the market for biopreservation, the application of biopreservation consists of therapeutic applications, research applications, clinical trials, and other applications. The biopreservation is primarily applied in therapeutics due to the advancements in regenerative medicine & customized medicine, an increase in the shift of cord blood banking, and the rising incidence of chronic diseases.

The end-users of the biopreservation market include biobanks, gene banks, hospitals, and other end users. The biobanks segment is expected to have a major share in the market. The major share of this segment is attributed to the increasing preference for the preservation of stem cells and the rising numbers of sperm and egg banks.

Further, according to the regional market of biopreservation, the North American region is recorded for the colossal share in the market. This is due to the continuous drug developments and the arrival of advanced therapies in the domain of biomedical research. Additionally, the increasing requirement of expensive and improved treatment for patients' chronic diseases is the key factor.

The rising incidence of chronic diseases, including cardiac, renal diseases, diabetes, and obesity, is the crucial factor that will propel the biopreservation market growth in the prevailing period. Government initiatives to encourage stem cell therapies to treat the disease, which will again propel market growth. Conversely, the strict regulations for producing biopreservation products and the evolution of room temperature storage procedures may limit the biopreservation market growth.

Merck KGaA, Avantor, Inc., Bio-Techne Corporation, BioLife Solutions, Inc., Thermo Fisher Scientific Inc, ThermoGenesis Holdings, Inc., Worthington Industries, Inc., Chart Industries, Inc, So-Low Environmental Equipment Co., Inc., Princeton BioCision, LLC, Shanghai Genext Medical Technology Co. Ltd, Exact Sciences Corporation, Helmer Scientific, Inc., CryoTech, Inc., Arctiko, Nippon Genetics Europe, PHC Holdings Corporation, STEMCELL Technologies, Inc., AMS Biotechnology, and OPS Diagnostics. These are the few companies list of the biopreservation market.

Since the rapid increase in the number of research and developments gives the way of potentials for market growth, the biopreservation of biological samples has become a crucial segment. This helps the researchers to access the data of the number of people by the preserved biological samples.

This research presents a thorough analysis of market share, the present trends, and forthcoming evaluations to explain the approaching investment pockets.

This research provides market insights from 2020 to 2026, which is predicted to allow the shareholders to capitalize on the forthcoming opportunities.

This report further offers comprehensive insights into the region, which helps to understand the geographical market and assist in strategic business planning and ascertain future opportunities.

Key Topics Covered:

1. Executive Summary

2. Industry Outlook2.1. Industry Overview2.2. Industry Trends

3. Market Snapshot3.1. Market Definition3.2. Market Outlook3.2.1. PEST Analysis3.2.2. Porter Five Forces3.3. Related Markets

4. Market characteristics4.1. Market Evolution4.2. Market Trends and Impact4.3. Advantages/Disadvantages of Market4.4. Regulatory Impact4.5. Market Offerings4.6. Market Segmentation4.7. Market Dynamics4.7.1. Drivers4.7.2. Restraints4.7.3. Opportunities4.8. DRO - Impact Analysis

5. Type: Market Size & Analysis5.1. Overview5.2. Biopreservation Media5.2.1. Nutrient Media5.2.2. Sera5.2.3. Growth Factors & Supplements5.3. Biospecimen Equipment5.3.1. Temperature Control Systems5.4. Freezers5.5. Cryogenic Storage Systems5.6. Thawing Equipment5.7. Refrigerators5.7.1. Accessories5.7.2. Alarms & Monitoring systems5.7.3. Incubators5.7.4. Centrifuges5.7.5. Other Equipment

6. Application: Market Size & Analysis6.1. Overview6.2. Therapeutic Applications6.3. Research Applications6.4. Clinical Trials6.5. Other Applications

7. End User: Market Size & Analysis7.1. Overview7.2. Biobanks7.3. Gene Banks7.4. Hospitals7.5. Other End Users

8. Geography: Market Size & Analysis8.1. Overview8.2. North America8.3. Europe8.4. Asia Pacific8.5. Rest of the World

9. Competitive Landscape9.1. Competitor Comparison Analysis9.2. Market Developments9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships9.2.2. Product Launches and execution

10. Vendor Profiles10.1. Merck KGaA10.1.1. Overview10.1.2. Financials10.1.3. Products & Services10.1.4. Recent Developments10.1.5. Business Strategy10.2. Avantor, Inc10.2.1. Overview10.2.2. Financials10.2.3. Products & Services10.2.4. Recent Developments10.2.5. Business Strategy10.3. Bio-Techne Corporation10.3.1. Overview10.3.2. Financials10.3.3. Products & Services10.3.4. Recent Developments10.3.5. Business Strategy10.4. BioLife Solutions, Inc10.4.1. Overview10.4.2. Financials10.4.3. Products & Services10.4.4. Recent Developments10.4.5. Business Strategy10.5. Thermo Fisher Scientific Inc10.5.1. Overview10.5.2. Financials10.5.3. Products & Services10.5.4. Recent Developments10.5.5. Business Strategy10.6. ThermoGenesis Holdings, Inc10.6.1. Overview10.6.2. Financials10.6.3. Products & Services10.6.4. Recent Developments10.6.5. Business Strategy10.7. Worthington Industries, Inc10.7.1. Overview10.7.2. Financials10.7.3. Products & Services10.7.4. Recent Developments10.7.5. Business Strategy10.8. Chart Industries, Inc10.8.1. Overview10.8.2. Financials10.8.3. Products & Services10.8.4. Recent Developments10.8.5. Business Strategy10.9. So-Low Environmental Equipment Co.,Inc10.9.1. Overview10.9.2. Financials10.9.3. Products & Services10.9.4. Recent Developments10.9.5. Business Strategy10.10. Princeton BioCision, LLC10.10.1. Overview10.10.2. Financials10.10.3. Products & Services10.10.4. Recent Developments10.10.5. Business Strategy

11. Companies to Watch11.1. Shanghai Genext Medical Technology Co. Ltd11.1.1. Overview11.1.2. Products & Services11.1.3. Business Strategy11.2. Exact Sciences Corporation11.2.1. Overview11.2.2. Products & Services11.2.3. Business Strategy11.3. Helmer Scientific, Inc11.3.1. Overview11.3.2. Products & Services11.3.3. Business Strategy11.4. CryoTech, Inc11.4.1. Overview11.4.2. Products & Services11.4.3. Business Strategy11.5. Arctiko11.5.1. Overview11.5.2. Products & Services11.5.3. Business Strategy11.6. Nippon Genetics Europe11.6.1. Overview11.6.2. Products & Services11.6.3. Business Strategy11.7. PHC Holdings Corporation11.7.1. Overview11.7.2. Products & Services11.7.3. Business Strategy11.8. STEMCELL Technologies, Inc11.8.1. Overview11.8.2. Products & Services11.8.3. Business Strategy11.9. AMS Biotechnology11.9.1. Overview11.9.2. Products & Services11.9.3. Business Strategy11.10. OPS Diagnostics11.10.1. Overview11.10.2. Products & Services11.10.3. Business Strategy

12. Analyst Opinion

13. Annexure13.1. Report Scope13.2. Market Definitions13.3. Research Methodology13.3.1. Data Collation and In-house Estimation13.3.2. Market Triangulation13.3.3. Forecasting13.4. Report Assumptions13.5. Declarations13.6. Stakeholders13.7. Abbreviations

For more information about this report visit https://www.researchandmarkets.com/r/711zgr

Story continues

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/worldwide-industry-for-biopreservation-to-2026---key-drivers-restraints-and-opportunities-301200103.html

SOURCE Research and Markets

More:
Worldwide Industry for Biopreservation to 2026 - Key Drivers, Restraints and Opportunities - Yahoo Finance

Recommendation and review posted by Bethany Smith

If you've ever wondered why we get goosebumps, you're in good company -- so did Charles Darwin, who mused about them in his writings on evolution. Goosebumps might protect animals with thick fur from the cold, but we humans don't seem to benefit from the reaction much -- so why has it been preserved during evolution all this time?

In a new study, Harvard University scientists have discovered the reason: the cell types that cause goosebumps are also important for regulating the stem cells that regenerate the hair follicle and hair. Underneath the skin, the muscle that contracts to create goosebumps is necessary to bridge the sympathetic nerve's connection to hair follicle stem cells. The sympathetic nerve reacts to cold by contracting the muscle and causing goosebumps in the short term, and by driving hair follicle stem cell activation and new hair growth over the long term.

Published in the journalCell, these findings in mice give researchers a better understanding of how different cell types interact to link stem cell activity with changes in the outside environment.

"We have always been interested in understanding how stem cell behaviors are regulated by external stimuli. The skin is a fascinating system: it has multiple stem cells surrounded by diverse cell types, and is located at the interface between our body and the outside world. Therefore, its stem cells could potentially respond to a diverse array of stimuli -- from the niche, the whole body, or even the outside environment," said Ya-Chieh Hsu, the Alvin and Esta Star Associate Professor of Stem Cell and Regenerative Biology, who led the study in collaboration with Professor Sung-Jan Lin of National Taiwan University. "In this study, we identify an interesting dual-component niche that not only regulates the stem cells under steady state, but also modulates stem cell behaviors according to temperature changes outside."

A system for regulating hair growth

Many organs are made of three types of tissue: epithelium, mesenchyme, and nerve. In the skin, these three lineages are organized in a special arrangement. The sympathetic nerve, part of our nervous system that controls body homeostasis and our responses to external stimuli, connects with a tiny smooth muscle in the mesenchyme. This smooth muscle in turn connects to hair follicle stem cells, a type of epithelial stem cell critical for regenerating the hair follicle as well as repairing wounds.

The connection between the sympathetic nerve and the muscle has been well known, since they are the cellular basis behind goosebumps: the cold triggers sympathetic neurons to send a nerve signal, and the muscle reacts by contracting and causing the hair to stand on end. However, when examining the skin under extremely high resolution using electron microscopy, the researchers found that the sympathetic nerve not only associated with the muscle, but also formed a direct connection to the hair follicle stem cells. In fact, the nerve fibers wrapped around the hair follicle stem cells like a ribbon.

"We could really see at an ultrastructure level how the nerve and the stem cell interact. Neurons tend to regulate excitable cells, like other neurons or muscle with synapses. But we were surprised to find that they form similar synapse-like structures with an epithelial stem cell, which is not a very typical target for neurons," Hsu said.

Next, the researchers confirmed that the nerve indeed targeted the stem cells. The sympathetic nervous system is normally activated at a constant low level to maintain body homeostasis, and the researchers found that this low level of nerve activity maintained the stem cells in a poised state ready for regeneration. Under prolonged cold, the nerve was activated at a much higher level and more neurotransmitters were released, causing the stem cells to activate quickly, regenerate the hair follicle, and grow new hair.

The researchers also investigated what maintained the nerve connections to the hair follicle stem cells. When they removed the muscle connected to the hair follicle, the sympathetic nerve retracted and the nerve connection to the hair follicle stem cells was lost, showing that the muscle was a necessary structural support to bridge the sympathetic nerve to the hair follicle.

How the system develops

In addition to studying the hair follicle in its fully formed state, the researchers investigated how the system initially develops -- how the muscle and nerve reach the hair follicle in the first place.

"We discovered that the signal comes from the developing hair follicle itself. It secretes a protein that regulates the formation of the smooth muscle, which then attracts the sympathetic nerve. Then in the adult, the interaction turns around, with the nerve and muscle together regulating the hair follicle stem cells to regenerate the new hair follicle. It's closing the whole circle -- the developing hair follicle is establishing its own niche," said Yulia Shwartz, a postdoctoral fellow in the Hsu lab. She was a co-first author of the study, along with Meryem Gonzalez-Celeiro, a graduate student in the Hsu Lab, and Chih-Lung Chen, a postdoctoral fellow in the Lin lab.

Responding to the environment

With these experiments, the researchers identified a two-component system that regulates hair follicle stem cells. The nerve is the signaling component that activates the stem cells through neurotransmitters, while the muscle is the structural component that allows the nerve fibers to directly connect with hair follicle stem cells.

"You can regulate hair follicle stem cells in so many different ways, and they are wonderful models to study tissue regeneration," Shwartz said. "This particular reaction is helpful for coupling tissue regeneration with changes in the outside world, such as temperature. It's a two-layer response: goosebumps are a quick way to provide some sort of relief in the short term. But when the cold lasts, this becomes a nice mechanism for the stem cells to know it's maybe time to regenerate new hair coat."

In the future, the researchers will further explore how the external environment might influence the stem cells in the skin, both under homeostasis and in repair situations such as wound healing.

"We live in a constantly changing environment. Since the skin is always in contact with the outside world, it gives us a chance to study what mechanisms stem cells in our body use to integrate tissue production with changing demands, which is essential for organisms to thrive in this dynamic world," Hsu said.

Read the rest here:
The real reason behind goosebumps - Jill Lopez

Recommendation and review posted by Bethany Smith

More than 25 years ago, it was a patient with a port-wine stain who inspired Alster to learn more about the then-fledgling world of lasers. Alster accepted a fellowship in Boston, where her patient traveled to receive treatments. So in essence, I changed her life because I significantly lightened the birthmark to the point where she didn't need to cover it, says Alster. And she changed my life because I wouldn't have looked into lasers if it wasn't for her... I ended up opening up my own center in Washington, D.C. in 1990. And at that time it was the only freestanding laser center in the world.

Lasers and Scars

Lasers can treat many types of scars, including surgical scars, acne scars, and scars from injuries. They penetrate the epidermis to stimulate new, healthy skin cell growth. The most common lasers used in scar removal are ablative fractional carbon dioxide lasers, Nd:YAG, nonablative fractional lasers, and pulsed dye lasers.

Lasers and Hair Removal

Laser hair removal is a medical procedure that uses a concentrated beam of light to remove unwanted hair. The laser emits a light that is absorbed by the pigment (melanin) in the hair. The light energy is converted to heat, which then damages the hair follicles that produce hairs. This damage inhibits or delays future hair growth. With repeated treatments, laser hair removal can permanently reduce unwanted hair. While all hairs dont fall out immediately, they will shed within days to weeks of treatment.

But lasers arent only used for hair reduction. Low-Level Laser Therapy (LLLT) is a relatively new treatment that uses low-power lasers to stimulate hair growth. Its hypothesized that LLLT stimulates stem cells in the hair follicle and shifts the follicles in the anagen (growth) stage of the hair cycle.

How is LED different from lasers?

Commonly confused with lasers, light-emitting diodes (LED) can reduce fine lines, increase collagen production, and smooth skin by using varying color wavelengths of visible LED light. Lasers, on the other hand, often use a single wavelength, and the beam is ideal for stimulating changes that only respond to very specific wavelengths (hair removal, dark spot removal, etc.).

Can you combine lasers with other in-office treatments in the same session?

Short answer: Yes! Depending on the laser you and your dermatologist choose, you can get filler or Botox in the same treatment. Some experts will specifically recommend injectables with Fraxel within the same appointment since its considered safe and delivers a rather dramatic final result. Alster often combines non-ablative laser treatments with microneedling to amplify the effects.

Can you be too young for lasers?

When deciding whether or not to try a laser, your age shouldnt be a major deciding factor. It's more of a matter of the problem you want to fix, not how old you are. Many young people have rosacea, acne, sun spots, and sun damage all of which are treatable with lasers. Still, less-intensive therapies, such as chemical peels, are likely enough to repair young, relatively healthy skin (and are often less expensive).

Is it safe to laser your skin at home?

There are various options for at-home laser treatments that you can use safely. Typically, at-home devices have significantly lower power than those used in a medical setting, in order to reduce risks. Many lasers for wrinkles or acne are simply LED light products, like the Dr. Dennis Gross Skincare DRx SpectraLite mask. There are, however, a few at-home non-ablative fractional lasers available, like the Tria SmoothBeauty Laser.

Michelles Current Favorites

While everyones skin is different and your personal dermatologist knows whats best for you Michelle says she slathered her face with Aquaphor following a Fraxel treatment. You really do need to keep your skin moist [afterward], she says. And then it's all about sunscreen, sunscreen, sunscreen. Right now, Michelle is into Dr. Loretta Urban Antioxidant Sunscreen SPF 40, which has a slight tint.

Jennys Current Favorites

Like Michelle, Jenny used Aquaphor after getting Fraxel. She also used CeraVe Moisturizing Cream post-treatment to help speed up healing. And in order to cover up the sandpaper-like texture and small, dark dots that often arise after getting Fraxel, Jenny used Oxygenetix Oxygenating Foundation. A lot of dermatologists and plastic surgeons recommend it for people to use this when they're healing, she says. It's thicker than what I would normally use for foundation, but it gave a really seamless finish [and] got me through that week or two after [treatment].

Like many in-office treatments, lasers often come with some downtime. But good things come to those who wait: Lasers can have a huge impact on the look and health of your skin.

View original post here:
The Complete Guide to Laser Treatments for Hair and Skin | The Science of Beauty Podcast | Allure - Allure

Recommendation and review posted by Bethany Smith

What happened

CRISPR gene-editing stocks are being hit hard by a broader biotech sell-off on Tuesday. Shares of CRISPR Therapeutics (NASDAQ:CRSP) were down 9.1% as of 12:05 p.m. EST. Editas Medicine (NASDAQ:EDIT) stock had declined 13.7%, while Intellia Therapeutics (NASDAQ:NTLA) shares had slumped 11.4%.

There wasn't a clear reason behind today's rout of biotech stocks. The biggest negative story in the biopharmaceutical industry centered on Arcturus Therapeutics' disappointing early-stage results for its single-dose COVID-19 vaccine candidate.

Image source: Getty Images.

CRISPR Therapeutics, Editas, and Intellia tend to be more volatile than most stocks. None of the companies have products on the market yet. Their valuations are based solely on investors' optimism about their future prospects. When that optimism wanes, the stocks sink.

It's important to keep in mind, though, that nothing has actually changed about the prospects for any of these three gene-editing biotechs. In many ways, those prospects are as strong as they've ever been.

CRISPR Therapeutics and its big partner, Vertex Pharmaceuticals, reported encouraging new data earlier this month for experimental gene-editing therapy CTX001 in treating rare genetic blood disorders beta-thalassemia and sickle cell disease. Editas also announced positive preclinical data for its candidate targeting the same diseases a few weeks ago and filed for U.S. regulatory clearance to begin a phase 1 clinical study in treating sickle cell disease. Intellia presented promising preclinical data in early December for its experimental gene-editing therapies targeting acute myeloid leukemia (AML) and rare genetic disease alpha-1 antitrypsin deficiency.

Each of these stocks is falling today based on no news directly related to their businesses or pipelines. That creates a buying opportunity for investors who remain confident about each company's direction.

What really matters for these three biotechs is the clinical progress for their respective pipeline candidates. And key developments are on the way for all three companies.

CRISPR Therapeutics expects to report additional data from early-stage studies of immuno-oncology candidates CTX110, CTX120, and CTX130 in 2021. Editas hopes to begin a phase 1 study evaluating EDIT-301 in treating sickle cell disease and continue patient enrollment in a phase 1 study of EDIT-101 in treating eye disease Leber congenital amaurosis type 10 (LCA10) in the new year. Intellia anticipates submitting for regulatory clearance to begin early-stage studies of NTLA-5001 in treating AML and for NTLA-2002 in treating hereditary angioedema next year.

View original post here:
Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking Today - The Motley Fool

Recommendation and review posted by Bethany Smith

The 65 rating InvestorsObserver gives to Crispr Therapeutics AG (CRSP) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 80 percent of stocks in the Biotechnology industry, CRSPs 65 overall rating means the stock scores better than 65 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Crispr Therapeutics AG (CRSP) stock is down -4.15% while the S&P 500 is higher by 0.12% as of 10:57 AM on Tuesday, Dec 29. CRSP is down -$7.01 from the previous closing price of $168.93 on volume of 2,016,389 shares. Over the past year the S&P 500 has risen 16.09% while CRSP is higher by 161.84%. CRSP lost -$3.25 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

View original post here:
Should Crispr Therapeutics AG (CRSP) be in Your Portfolio? - InvestorsObserver

Recommendation and review posted by Bethany Smith

Here with your Southeast Regional Ag Report, Im Tim Hammerich.

Its nearly impossible to talk about the Florida citrus industry in 2020, without at least mentioning citrus greening disease. Otherwise known as huanglongbing, citrus greening is spread by the asian citrus psyllid which serves as a vector for the disease.

Citrus greening has done enormous damage to the Florida citrus industry despite years of research to try to develop effective management tools. Scientists are now hopeful that CRISPR can help. The tool for editing genomes, allows breeders to select for very specific traits, and iterate more quickly.

And they have a roadmap to follow. CRISPR has been used to develop resistant varieties to citrus canker. A program started in 2013 was able to identify the citrus canker susceptibility gene in 2014, and through CRISPR found a way to knock out this susceptibility gene. They have now made, this year, citrus varieties that are resistant to citrus canker.

Dr. Nian Wong, professor at the Citrus Research at Education Center for the University of Florida IFAS at Lake Alfred, says they were able to make progress on citrus canker much quicker than traditional breeding, and he hopes this can also be applied to citrus greening.

While there can be no guarantees on timing, Dr. Wong hopes that progress can be made on citrus greening on a similar timeline to what theyve been able to do these past seven years with citrus canker.

Original post:
Can CRISPR Save Florida Citrus? - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West

Recommendation and review posted by Bethany Smith

Apart from new findings on coronavirus every single day, the year was also filled with stories from outer space, archeology and anatomy

The year 2020 also termed as the year of the pandemic, social distancing, work from home, was also the year of research at breakneck speed. Virologists, immunologists, computational biologists, epidemiologists, and medical professionals across the globe turned into superheroes without capes.

Quick sequencing of the whole genome of the novel coronavirus (SARS-CoV-2) helped develop various test kits. We now have not one or two, but multiple COVID-19 vaccines that have succeeded in human clinical trials. Moderna's and Pfizer-BioNTechs vaccines that use messenger RNA have reported efficacy of about 95%, and the United Kingdom, the United States and the United Arab Emirates have already launched mass vaccinations.

Apart from new findings on coronavirus every single day, the year was also filled with stories from outer space, archeology and anatomy. Here is a list of a few of them in random order

In October, NASA confirmed, for the first time, water on the sunlit side of the Moon indicating that water may be distributed across the moons surface, and not limited to the cold and shadowed side.

Researchers from the Netherlands Cancer Institute announced in October that they have discovered a new pair of salivary glands hidden between the nasal cavity and throat. The team proposed the name tubarial glands and noted that this identification could help to explain and avoid radiation-induced side-effects such as trouble during eating, swallowing, and speaking.

In September, an international scientific team announced that they have spotted phosphine gas on Venus. On Earth, microorganisms that live in anaerobic (with no oxygen) environments produce phosphine. Massachusetts Institute of Technology molecular astrophysicist and study co-author Clara Sousa-Silva said in a release, This is important because, if it is phosphine, and if it is life, it means that we are not alone. It also means that life itself must be very common, and there must be many other inhabited planets throughout our galaxy.

Read our detailed explainer here.

In March, a person suffering from Leber congenital amaurosis, a rare inherited disease that leads to blindness, became the first to have CRISPR/Cas-9-based therapy directly injected into the body.

In June, two patients with beta-thalassemia and one with sickle cell disease had their bone marrow stem cells edited using CRISPR techniques.

Click here to read our explainer on the genome-editing tool that won this years Nobel Prize for Chemistry.

The year 2020 marks 100 years of discovery of Indus Valley Civilisation, and a new study showed that dairy products were being produced by the Harappans as far back as 2500 BCE.

Another study found the presence of animal products, including cattle and buffalo meat, in ceramic vessels dating back about 4,600 years.

Chinas Change-5 probe brought back about 1,731 grams of samples from the moon becoming the third country to bring moon samples after the U.S and Soviet Union.

Also, Japans Hayabusa 2 brought back the first extensive samples from an asteroid. The spacecraft, launched from Japan's Tanegashima space centre in 2014, took four years to reach the asteroid Ryugu before taking a sample and heading back to Earth in November 2019.

Mars rover Perseverance blasted off for the red planet on July 30 to bring the first Martian rock samples back to Earth. If all goes well, the rover will descend to the Martian surface on February 18, 2021.

You have reached your limit for free articles this month.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Support Quality Journalism.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.

Excerpt from:
2020: The year science took centre-stage - The Hindu

Recommendation and review posted by Bethany Smith

For obvious reasons, 2020 will not go down as a good year. At the same time, it has brought more scientific progress than any year in recent memory and these advances will last long after COVID-19 as a major threat is gone.

Two of the most obvious and tangible signs of progress are the mRNA vaccines now being distributed across America and around the world. These vaccines appear to have very high levels of efficacy and safety, and they can be produced more quickly than more conventional vaccines. They are the main reason to have a relatively optimistic outlook for 2021. The mRNA technology also may have broader potential, for instance by helping to mend damaged hearts.

Other advances in the biosciences may prove no less stunning. A very promising vaccine candidate against malaria, perhaps the greatest killer in human history, is in the final stages of testing. Advances in vaccine technology have created the real possibility of a universal flu vaccine, and work is proceeding on that front. New CRISPR techniques appear on the verge of vanquishing sickle-cell anemia, and other CRISPR methods have allowed scientists to create a new smartphone-based diagnostic test that would detect viruses and offer diagnoses within half an hour.

It has been a good year for artificial intelligence as well. GPT-3 technology allows for the creation of remarkably human-like writing of great depth and complexity. It is a major step toward the creation of automated entities that can react in very human ways. DeepMind, meanwhile, has used computational techniques to make major advances in protein folding. This is a breakthrough in biology that may lead to the easier discovery of new pharmaceuticals.

One general precondition behind many of these advances is the decentralized access to enormous computing power, typically through cloud computing. China seems to be progressing with a photon method for quantum computing, a development that is hard to verify but could prove to be of great importance.

Computational biology, in particular, is booming. The Moderna vaccine mRNA was designed in two days, and without access to COVID-19 itself, a remarkable achievement that would not have been possible only a short while ago. This likely heralds the arrival of many other future breakthroughs from computational biology.

It also has been a good year for progress in transportation.

Driverless vehicles appeared to be stalled, but Walmart will be using them on some truck deliveries in 2021. Boom, a startup that is pushing to develop feasible and affordable supersonic flight, now has a valuation of over $1 billion, with prototypes expected next year. SpaceX achieved virtually every launch and rocket goal it had announced for the year. Toyota and other companies have announced major progress on batteries for electric vehicles, and the related products are expected to debut in 2021.

All this will prove a boon for the environment, as will progress in solar power, which in many settings is as cheap as any relevant alternative.

In previous eras, advances in energy and transportation typically have brought further technological advances, by enabling humans to conquer and reshape their physical environments in new and unexpected ways. We can hope that general trend will continue.

Finally, while not quite meeting the definition of a scientific advance, the rise of remote work is a real breakthrough. Many more Zoom meetings will be held, and many business trips will never return. Many may see this as a mixed blessing, but it will improve productivity significantly.

Without a doubt, it has been a tragic year. Alongside the sadness and failure, however, there has been quite a bit of progress. Thats something worth keeping in mind, even if we cant quite bring ourselves to celebrate, as we look back on 2020.

Tyler Cowen is a syndicated columnist.

Follow this link:
2020 was a tough year, but there is a silver lining - Boston Herald

Recommendation and review posted by Bethany Smith

The "Genetic Testing. Global Market Forecasts for Applications and Technologies. Updated for COVID-19 Pandemic Impact with Executive and Consultant Guides 2021 to 2025" report has been added to ResearchAndMarkets.com's offering.

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry.

The traditional genetic testing market is growing in volume and growing in the breadth of tests creating a new life for the industry. The report forecasts the market size out to 2025. The report includes detailed breakouts for 14 countries and 5 regions.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

Companies Mentioned

10x Genomics, Inc

23andME Inc

Abbott Diagnostics

AccuraGen Inc

Adaptive Biotechnologies

Admera Health, LLC

Agena Bioscience, Inc

Agilent

Akonni Biosystems

Ancestry.com LLC

Anchor Dx

ArcherDx, Inc

ARUP Laboratories

Asuragen

Baylor Miraca Genetics Laboratories

Beckman Coulter, Inc

Becton, Dickinson and Company

BGI Genomics Co. Ltd

Bio-Rad Laboratories, Inc

Bio-Techne

Bioarray Genetics

Biocept, Inc

Biodesix Inc

BioFluidica

BioGenex

Biolidics Ltd

bioMerieux Diagnostics

Bioneer Corporation

Cancer Genetics

Caris Molecular Diagnostics

CellMax Life

Centogene

Chronix Biomedical

Circulogene

Clinical Genomics

And Many More Companies!

1. Introduction and Market Definition

1.1 Genetic Testing Definition in This Report

1.2 The Genomics Revolution

1.3 Market Definition

1.3.1 Revenue Market Size

1.3.1 Newborn Screening

1.3.2 Non Invasise Pregnancy Testing

1.3.3 Predictive

1.3.4 Oncology

Story continues

1.3.5 Direct to Consumer

1.3.6 Other Application

1.3.7 PCR

1.3.4 NGS

1.3.5 Cytogenetic

1.3.6 Other Technology

1.4 U.S. Medical Market and laboratory Testing - Perspective

1.4.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

2.1 Market Participants Play Different Roles

2.1.1 Supplier/pharmaceutical

2.1.2 Independent lab specialized/esoteric

2.1.3 Independent lab national/regional

2.1.4 Independent lab analytical

2.1.5 Public National/regional lab

2.1.6 Hospital lab

2.1.7 Physician lab

2.1.8 DTC Lab

2.1.9 Independent Genetic Testing Lab

2.1.10 Audit Body

2.2 Genetic Tests -Types, Examples and Discussion

2.2.1 Preimplantation Genetic Diagnosis- An Emerging Market

2.2.2 Prenatal Diagnosis - New Technologies Create Opportunity

2.2.3 Newborn Screening

2.2.2 Diagnostic Testing

2.2.3 Carrier Testing

2.2.6 Predictive and Presymptomatic Testing

2.2.7 Pharmacogenomics

2.2.8 Forensic Testing

2.2.9 Parental Testing

2.2.10 Ancestral Testing

2.3 Industry Structure

2.3.1 Hospital's Testing Share

2.3.2 Economies of Scale

2.3.2.1 Hospital vs. Central Lab

2.3.3 Physician Office Lab's

2.3.4 Physician's and POCT

2.4 Market Shares of Key Genetics Players - Analysis

3. Market Trends

3.1 Factors Driving Growth

3.1.1 Genetic Discoveries Creating New Diagnostic Markets

3.1.2 Aging Population a Boon for Diagnostics

3.1.3 Pharmacogenomics Drives Further Growth

3.1.4 Oncology and Liquid Biopsy Enter New Era

3.1.5 Fertility Practice Growth drives market

3.1.6 Direct to Consumer begins to break out

3.2 Factors Limiting Growth

3.2.1 Increased Competition Lowers Price

3.2.2 Lower Costs

Read more from the original source:
Global Genetic Testing Market Forecasts for Applications and Technologies to 2025 - ResearchAndMarkets.com - Yahoo Finance

Recommendation and review posted by Bethany Smith

This article was originally published here

Clin Gastroenterol Hepatol. 2020 Dec 24:S1542-3565(20)31721-3. doi: 10.1016/j.cgh.2020.12.025. Online ahead of print.

ABSTRACT

BACKGROUND AND AIMS: Up to 20% of younger patients (age <50 years) diagnosed with colorectal cancer (CRC) have germline mutations in cancer susceptibility genes. Germline genetic testing may guide clinical management and facilitate earlier intervention in affected relatives. Few studies have characterized differences in genetic testing by race/ethnicity.

METHODS: We identified young adults (age 18-49 years) diagnosed with CRC between 2009 and 2017 in two health systems in Dallas, TX. We evaluated referral to genetic counseling, attendance at genetic counseling appointments, and receipt of germline genetic testing by race/ethnicity.

RESULTS: Of 385 patients with young-onset CRC (median age at diagnosis 44.4 years), 176 (45.7%) were Hispanic, 98 (25.4%) non-Hispanic Black, and 111 (28.8%) non-Hispanic White. Most patients (76.9%) received immunohistochemistry (IHC) for mismatch repair proteins, and there was no difference in receipt of IHC by race/ethnicity. However, a lower proportion of Black patients were referred to genetic counseling (50.0% vs. White patients 54.1% vs. Hispanic patients 65.9%, p=0.02) and attended genetic counseling appointments (61.2% vs. 81.7% White patients vs. 86.2% Hispanic patients, p<0.01). Of 141 patients receiving genetic testing, 38 (27.0%) had a pathogenic or likely pathogenic variant in a cancer susceptibility gene. An additional 33 patients (23.4%) had variants of uncertain significance, of which 84.8% occurred in racial/ethnic minorities.

CONCLUSION: In a diverse population of patients diagnosed with young-onset CRC, we observed racial/ethnic differences in referral to and receipt of germline genetic testing. Our findings underscore the importance of universal genetic testing to address racial/ethnic disparities in young-onset CRC.

PMID:33359728 | DOI:10.1016/j.cgh.2020.12.025

Read more here:
Racial and ethnic disparities in germline genetic testing of patients with young-onset colorectal cancer - DocWire News

Recommendation and review posted by Bethany Smith

In August 2020, the FDA approved the first diagnostic test that combines next-generation sequencing and liquid biopsy. The test is intended to help guide treatment decisions for patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in metastatic nonsmall cell lung cancer (NSCLC), which is particularly deadly. The FDA called it a new era for mutation testing. The approval was granted to Guardant360CDx to provide information on multiple solid tumor biomarkers and to help identify EGFR mutations in patients who will benefit from treatment with osimertinib (Tagrisso), which is approved for a form of metastatic NSCLC.

Read the full article here.

4. Dr Andre Goy Discusses What Weve Learned About CAR T Therapies and Cytokine Responses

In a video interview, Andre Goy, MD,chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ,discussed what has been learned from existing chimeric antigen receptor T (CAR T)-cell therapies in managing cytokine responses.

Watch the interview here.

3. OneOncology, Foundation Medicine Create Partnership to Deliver Targeted Care

Also in August 2020, OneOncology, a network of nearly 170 community oncology care sites, and cancer genomic profiling firm Foundation Medicine announced a partnership to give patients and physicians access to genomic profiling tools as well as expanded research opportunities. In addition, OneOncology will help Foundation Medicine to create new assays for community oncology practices.

Read the full article here.

2. Broad Testing for Multiple Genes Benefits Patients With Cancer, Relatives

A study published in JAMA Oncology described how universalmultigene panel testingwas linked with increased detection of actionable, heritable variants beyond what one would expect to find using targeted genetic testing based on current cancer guidelines. The multicenter cohort study found that 1 in 8 patients had a pathogenic germline variant, half of which would not have been found if using guidelines alone. In addition, for the nearly 30% of patients with a high-penetrance variant, the findings led to a change in treatment.

Read the full article here.

1. How DNA Medicines Could Transform Treatment of Glioblastoma Multiforme

In an article appearing in the August 2020 edition of Evidence-Based Oncology, Jeffrey Skolnick, MD, the vice president of clinical development at biotech firm Inovio, discusses the companys proprietary technology that uses a computer algorithm to build DNA medicines that can target almost any antigen that can be presented to the human immune system through the major histocompatibility class I system. DNA medicines are built in the form of circular strands of synthetic DNA called plasmids, which can neither propagate nor integrate into the human genome. He also discusses their use in a potential application for glioblastoma, which is incurable.

Read the full article here.

Visit link:
The Top 5 Most-Read Precision Oncology Articles of 2020 - AJMC.com Managed Markets Network

Recommendation and review posted by Bethany Smith